About vinorelbine tartrate
Vinca alkaloid chemotherapy medicine
Used for
- Non-small cell lung cancer
- Advanced breast cancer
Usual adult dose
Usually 25–30 mg/m² intravenously once weekly; dosing depends on cancer and treatment plan.
Common side effects
- Low blood cell counts, increasing infection or bleeding risk
- Nausea, vomiting, constipation, or diarrhoea
- Tiredness and hair loss
- Injection-site irritation or tissue injury if leakage occurs
Important warnings
- Can cause severe bone-marrow suppression and infection.
- Must be given intravenously by trained staff; never administer into the spinal fluid.
- Liver problems may require dose reduction; blood counts need monitoring.
- Avoid live vaccines and promptly report fever or unusual bleeding.
Pregnancy
May harm an unborn baby. Avoid pregnancy during treatment; discuss reliable contraception with the oncology team.
Breastfeeding
Breastfeeding is not recommended during treatment and for a period afterward; confirm timing with the oncology team.
Interactions
- Other medicines that suppress bone marrow can increase blood-related toxicity.
- Strong CYP3A inhibitors or inducers may alter vinorelbine levels.
- Mitomycin may increase risk of lung toxicity.
- Grapefruit may affect drug levels; avoid unless the oncology team approves.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.